Growth in the Indian Dermal Fillers Market

The Indian dermal fillers market is expected to grow at the highest CAGR of 8.9% during the forecast period (2025-2031). The market growth is driven by rising disposable income, a high proportion of middle-aged people, and increasing awareness of cosmetic procedures. The market is growing with the number of dermatological consultations, dermatology clinics, and the increasing demand for dermatologists in the region. Additionally, the consistent growth of the Indian pharmaceutical industry contributes to the market growth. Furthermore, socio-economic changes and urbanization are propelling the regional market. The increasing penetration of foreign pharma companies is additionally presenting a significant opportunity for the Indian market. 

Indian dermal fillers market is segmented by application (face-lift, lip treatment/enhancement, facial line correction treatment, and others), by type (collagen fillers, poly-l-lactic acid, hyaluronic acid, calcium hydroxylapatite, and others), and by end-user (dermatology hospital and clinics). 

Key players operating in the Indian dermal fillers market include Allergan PLC, Galderma Laboratories, L.P., Merz Pharmaceuticals GmbH, Cynosure LLC, Prollenium Medical Technologies, Inc., and Teoxane SA. The companies adopt various strategies such as partnerships & collaborations, new product launches, and more, contributing significantly to the market growth. 

Recent Developments 

• In September 2023, the Menarini Group launched A. Menarini India Private Ltd. in India. The company has expanded its line of fillers and threads from RELIFE, by introducing ‘Definisse® Core Filler’ to India. 

• In July 2023, the FDA updated its webpage on Dermal Fillers (Soft Tissue Fillers) informing about the delayed onset inflammation such as swelling or redness that can develop near the dermal filler injection site. It can additionally be followed by viral or bacterial illnesses or infections, vaccinations, or dental procedures. The inflammation is responsive to treatment or resolves on its own.

• In August 2022, Allergan Healthcare India Private Ltd. launched Juvéderm VOLUX in India. The product was approved by the Central Drugs Standards Control Organization (CDSCO). It is a combination of Hyaluronic acid 25 mg + Lidocaine hydrochloride 3 mg and is an injectable implant intended to restore and create volume in the face. 

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/indian-dermal-fillers-market